Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
2
pubmed:dateCreated
2010-1-15
pubmed:abstractText
Targeted therapeutics have significantly changed the outcome for patients diagnosed with cancer. Still, effective therapeutic intervention does not exist for many cancers and much remains to be done. The objective of this study was to identify novel genes that potentially regulate tumor growth, to target these gene products with monoclonal antibodies, and to examine the therapeutic potential of these antibodies.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jan
pubmed:issn
1078-0432
pubmed:author
pubmed:issnType
Print
pubmed:day
15
pubmed:volume
16
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
497-508
pubmed:meshHeading
pubmed-meshheading:20068083-Animals, pubmed-meshheading:20068083-Antibodies, Monoclonal, pubmed-meshheading:20068083-Antineoplastic Agents, pubmed-meshheading:20068083-Cancer Vaccines, pubmed-meshheading:20068083-Cell Proliferation, pubmed-meshheading:20068083-Dose-Response Relationship, Drug, pubmed-meshheading:20068083-Humans, pubmed-meshheading:20068083-Immunotherapy, pubmed-meshheading:20068083-Mice, pubmed-meshheading:20068083-Mice, Inbred BALB C, pubmed-meshheading:20068083-NIH 3T3 Cells, pubmed-meshheading:20068083-Neoplasm Metastasis, pubmed-meshheading:20068083-Neoplasms, pubmed-meshheading:20068083-Signal Transduction, pubmed-meshheading:20068083-Tumor Burden, pubmed-meshheading:20068083-Tumor Cells, Cultured, pubmed-meshheading:20068083-Tumor Necrosis Factors, pubmed-meshheading:20068083-Xenograft Model Antitumor Assays
pubmed:year
2010
pubmed:articleTitle
Antibodies to TWEAK receptor inhibit human tumor growth through dual mechanisms.
pubmed:affiliation
Facet Biotech, Redwood City, California 94063, USA. patricia.culp@facetbiotech.com
pubmed:publicationType
Journal Article